IRON Stock Forecast: Disc Medicine, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Disc Medicine, Inc. hold a median 12-month price target of $127 — +68.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 42 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Disc Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (76): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IRON stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IRON, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.9% from it.
Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | Cantor Fitzgerald | Reiterates | Overweight | $170 |
| 18 Nov 2026 | Morgan Stanley | Maintains | Overweight | $92 → $104 |
| 9 Nov 2026 | Guggenheim | Initiates | Buy | $132 |
| 6 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $120 → $127 |
| 20 Oct 2026 | Morgan Stanley | Maintains | Overweight | $90 → $92 |
| 20 Oct 2026 | Truist Securities | Maintains | Buy | $83 → $115 |
| 20 Oct 2026 | Wedbush | Maintains | Outperform | $100 → $110 |
| 20 Oct 2026 | Wells Fargo | Maintains | Overweight | $86 → $124 |
| 19 Oct 2026 | BMO Capital | Maintains | Outperform | $100 → $120 |
| 19 Oct 2026 | Cantor Fitzgerald | Maintains | Overweight | $125 → $170 |
| 16 Sept 2026 | Wells Fargo | Maintains | Overweight | $79 → $86 |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | $100 |
| 2 Sept 2026 | Wedbush | Maintains | Outperform | $88 → $100 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $118 → $120 |
| 16 June 2026 | Morgan Stanley | Maintains | Overweight | $80 → $85 |
| 10 June 2026 | Wedbush | Reiterates | Outperform | $88 |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 2 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 27 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 17 Feb 2026 | BMO Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRON.
This page is one stock. Monday covers all of them.
IRON appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IRON vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Disc Medicine, Inc. returned −16.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IRON analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 4.8×
- EV / EBITDA
- —
Cheaper than 19% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −41.3%
- Return on assets
- −24.9%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Disc Medicine, Inc. has a market value of $3.4B and an enterprise value of $2.8B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$245.9M.
Free cash flow in the twelve months to 30 June 2026: −$197.6M.
Disc Medicine, Inc. employs 173 people.
Data provided by Twelve Data
IRON and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IRON’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Disc Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IRON
What is the IRON stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Disc Medicine, Inc. have a median 12-month price target of $127, with estimates ranging from $104 to $170. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IRON stock a buy right now?
Of the 13 analysts covering Disc Medicine, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Disc Medicine, Inc. 42 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IRON?
As at 21 Nov 2026, Disc Medicine, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (76 of 100).
Will IRON stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +68.9% from the last close, and Ticker Nerd's factor model ranks Disc Medicine, Inc. 42 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IRON stock forecast for 2030?
No analyst covering Disc Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $104 to $170 over the next 12 months.
How has IRON stock performed over the past year?
Disc Medicine, Inc. returned -16.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Disc Medicine, Inc. do?
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s work centers on red blood cell biology, with programs designed to address disorders involving heme biosynthesis and iron homeostasis.
About Disc Medicine, Inc.
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s work centers on red blood cell biology, with programs designed to address disorders involving heme biosynthesis and iron homeostasis. Its current pipeline includes therapies in development for rare blood diseases such as erythropoietic porphyrias, Diamond-Blackfan anemia, anemia associated with myelofibrosis, and polycythemia vera. Disc Medicine operates as a research-driven biotech business, advancing both clinical and preclinical candidates aimed at modifying fundamental biological pathways rather than offering broad commercial products. Headquartered in Watertown, Massachusetts, Disc Medicine plays a specialized role in the hematology market by concentrating on diseases with significant unmet medical need and limited treatment options.
CEO Dr. John D. Quisel Esq., J.D., Ph.D. · 173 employees · United States · https://www.discmedicine.com